Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pharmacotherapeutic management of bipolar disorder has advanced considerably since the introduction of lithium therapy nearly 50 years ago. The sizable percentage of patients who do not respond adequately to lithium and/or are intolerant to its side effects has served as an impetus for identifying alternative pharmacotherapeutic agents. Recent advances in the understanding of the neurotransmitter systems and their receptors as it applies to treatment of bipolar disorder has, in part, led to progress in delineating applications of anticonvulsant/antiepileptic drugs (AEDs) in this area. Although the efficacy of many drugs has been evaluated in patients with this disorder, medication tolerability and adherence issues related to unfavorable side effect profiles are substantial impediments to the development of novel pharmacotherapies. The potential for excessive weight gain as a side effect of certain psychopharmacologic agents remains a concern to both clinicians and patients. METHOD: English-language literature from 1985-2001 in MEDLINE was searched for the terms bipolar disorder, anticonvulsant, antiepileptic, lithium, antipsychotic, weight, and compliance. This article reviewed current therapeutic options for bipolar disorder, including newer AEDs and atypical antipsychotic drugs, with emphasis on the issue of weight gain and possible approaches to minimizing this risk. RESULTS: Certain newer AEDs are characterized by more favorable safety and tolerability profiles that include weight loss as a desirable side effect. Because bipolar disorder is associated with unacceptably high rates of relapse, recurrence, and morbidity, the concept of pharmacotherapeutic efficacy logically not only includes symptom relief but also necessarily encompasses issues related to regimen tolerability and adherence. CONCLUSION: There is a need for guidelines to help physicians carefully formulate and individualize management plans to reach safe, effective, and cost-efficient patient outcomes. Monitoring the weight of patients with bipolar disorder and educating them regarding this issue should be standard components of any treatment plan.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The medications most commonly associated with weight gain are olanzapine, clozapine, risperidone, quetiapine, gabapentin, divalproex and lithium; with carbamazepine, lamotrigine, and ziprasidone being the safer or options associated with less weight gain.808”
Citations
Cites
Psychopharmacology: The Fourth Generation of Progress
Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Kuczmarski, R. J. (1994) · JAMA · doi:10.1001/jama.272.3.205 · Cited by 2,362
Spearing, M. K., Post, R. M., Leverich, G. S., Brandt, D., & Nolen, W. (1997) · Psychiatry Research · doi:10.1016/s0165-1781(97)00123-6 · Cited by 978
Olanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Tohen, M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.9.841 · Cited by 539
Calabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1106 · Cited by 498
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446
Gabapentin in bipolar disorder: a placebo‐controlled trial of adjunctive therapy1
Pande, A. C., Crockatt, J. G., Janney, C. A., Werth, J. L., Tsaroucha, G., & Gabapentin Bipolar Disorder Study Group (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.20305.x · Cited by 313
Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.4.431 · Cited by 266
Cited by
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
STIGMA: BARRIER TO MENTAL HEALTH CARE AMONG ETHNIC MINORITIES
Gary, F. A. (2005) · Issues in Mental Health Nursing · doi:10.1080/01612840500280638 · Cited by 613
“Kafkaesque nightmares sometimes emerge within families as they ponder how, when, why, and under what circumstances these horrific illnesses occurred in their family members (Adshead, 2003; Anderson & Nickerson, 2005; Lefley, 1989; Nemeroff, 2003; Pinel, 1999; Szasz, 2003).”
BackgroundAsenapine: a novel psychopharmacologic agent with a unique human receptor signature
Shahid, M., Walker, G., Zorn, S., & Wong, E. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881107082944 · Cited by 493
Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians
Fagiolini, A., Frank, E., Scott, J. A., Turkin, S., & Kupfer, D. J. (2005) · Bipolar Disorders · doi:10.1111/j.1399-5618.2005.00234.x · Cited by 449
Metadata
- Authors
- Nemeroff, C. B.
- Affiliations
- Emory University (US)
- Corresponding author
- Nemeroff, Charles B.
- ORCID
- Nemeroff, Charles B.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2003-05-15
- Volume
- 64
- Issue
- 5
- Pages
- 532-539
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2094246063
- Cited by
- 86
- References
- 55
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 1 · 2018: 2 · 2017: 2 · 2016: 4 · 2014: 2 · 2013: 6 · 2012: 3
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- bipolar disorder, drug safety, lithium, atypical antipsychotics, weight gain, medication adherence, tolerability, weight loss, relapse prevention
- MeSH terms
- Topiramate, Anticonvulsants, Bipolar Disorder, Clinical Protocols, Female, Fructose, Humans, Lithium, Obesity, Patient Compliance, Patient Education as Topic, Antipsychotic Agents, Weight Gain, Weight Loss, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain. https://app.cochat.ai/papers/10.4088/jcp.v64n0506
- The paper
- Nemeroff, C. B. (2003). Safety of Available Agents Used to Treat Bipolar Disorder: Focus on Weight Gain. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v64n0506
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.